The Treatment of Ledipasvir/Sofosbuvir in Patients with Chronic Hepatitis C Virus: The Results of Five-year Follow-up
Yükleniyor...
Dosyalar
Tarih
2021
Yazarlar
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Galenos Yayincilik
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
Objectives: Chronic hepatitis C virus (HCV) is a fundamental worldwide health challenge. We assessed the treatment outcomes of ledipasvir (LDV) and sofosbuvir (SOF) with and without ribavirin (RBV) for 12 and 24 weeks in pre-treated and treatment-naive patients with chronic HCV. Materials and Methods: Totally 65 patients were included in the present study. Patients were divided in two groups. In the first group, LDV and SOF with RBV were administered to 12 patients for 12 weeks. In the second group, LDV and SOF without RBV were administered to 53 patients for 24 weeks. Results: Sustained virological response (SVR) rates were 100% for the both groups included in the study. The adverse events were weakness (15.39%), pruritus (6.15%), myalgia (4.62%) nausea (3.08%), dry mouth (1.54%) and anorexia (1.54%) in all patients. HCV-RNA was also negative in all patients 48 weeks after the beginning of the treatment. At the end of the fifth year of treatment, all the patients still had SVR and no recurrence was detected. Conclusion: In the treatment of patients with chronic HCV, LDV and SOF with and without RBV were highly effective. SVR rate of 100% was achieved in all pre-treated or treatment naive patients with or without cirrhosis regardless of genotype of HCV.
Açıklama
Anahtar Kelimeler
Chronic Hepatitis C Virus; Direct-Acting Antiviral Agents; Sofosbuvir; Ledipasvir, Fixed-Dose Combination; Genotype 1 Infection; Long-Term Outcomes; Sofosbuvir; Hcv; Ledipasvir; Ribavirin; Efficacy
Kaynak
Viral Hepatit Dergisi-Viral Hepatitis Journal
WoS Q Değeri
N/A
Scopus Q Değeri
Cilt
27
Sayı
3
